Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Rheumatoid Arthritis
NCT07745426Phase 2Recruiting
- Sponsor
- Tanta University
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial of diosmin and rebamipide in rheumatoid arthritis (RA) (3 arms), sponsored by Tanta University. Primary endpoints: Disease Activity Score-CRP at 3 months and Health Assessment Questionnaire-Disability Index at 3 months. Started Aug 2026; status: recruiting.
02
Drugs
diosminrebamipide
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07745426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745426.